

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Proposed Single Technology Appraisal (STA)

## Faldaprevir for treating genotype 1 chronic hepatitis C

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<u>Manufacturers/sponsors</u> <ul style="list-style-type: none"> <li>Boehringer Ingelheim (faldaprevir)</li> </ul> <u>Patient/carer groups</u> <ul style="list-style-type: none"> <li>Action on Hepatitis C</li> <li>Addiction Today (Addiction Recovery Foundation)</li> <li>Afiya Trust</li> <li>African Policy Network</li> <li>Alliance</li> <li>AVERT</li> <li>Black Health Agency</li> <li>British Liver Trust</li> <li>Compass UK</li> <li>Drugscope</li> <li>Equalities National Council</li> <li>GMFA - The Gay Men's Health Charity</li> <li>Hepatitis A –Z</li> <li>Hepatitis C Trust</li> <li>Muslim Council of Britain</li> <li>Muslim Health Network</li> <li>NAM Publications</li> <li>National AIDS Trust</li> <li>Positively UK</li> <li>Release</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Terrence Higgins Trust</li> <li>Transplant Support Network</li> <li>UK Harm Reduction Alliance</li> </ul> <u>Professional groups</u> <ul style="list-style-type: none"> <li>Association for Clinical Biochemistry Microbiology Group</li> <li>Association of Nurses in Substance</li> </ul>	<u>General</u> <ul style="list-style-type: none"> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Commissioning Support Appraisals Service</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Commercial Medicines Unit</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> </ul> <u>Possible comparator manufacturer(s)</u> <ul style="list-style-type: none"> <li>Roche Products (peginterferon alfa-2a and ribavirin)</li> <li>Merck Sharp and Dohme (peginterferon alfa-2b and ribavirin, boceprevir)</li> <li>Janssen (telaprevir)</li> </ul> <u>Relevant research groups</u> <ul style="list-style-type: none"> <li>Centre for Sexual Health &amp; HIV Research</li> <li>Cochrane Hepato-Biliary Group</li> <li>Foundation for Liver Research</li> <li>Health Research Authority</li> <li>MRC Clinical Trials Unit</li> <li>National Institute of Health Research</li> <li>Research Institute for the Care of Older People</li> </ul>

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of faldaprevir for treating genotype 1 chronic hepatitis C

Consultees	Commentators (no right to submit or appeal)
<p>Abuse</p> <ul style="list-style-type: none"> <li>British Association for Sexual Health and HIV</li> <li>British Association for Services to the Elderly</li> <li>British Association for the Study of the Liver</li> <li>British Association for the Study of the Liver Nurses Forum</li> <li>British Geriatrics Society</li> <li>British HIV Association</li> <li>British Infection Association</li> <li>British Liver Nurses Forum</li> <li>British Transplantation Society</li> <li>British Viral Hepatitis Group</li> <li>Health Protection Agency</li> <li>Hepatitis Nurse Specialist Forum</li> <li>Infection Control Nurses Association</li> <li>Medical Foundation for AIDS &amp; Sexual Health</li> <li>NHS Blood and Transplant</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society for General Microbiology</li> <li>United Kingdom Clinical Pharmacy Association</li> <li>United Kingdom Clinical Virology Network</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>Department of Health</li> <li>NHS England</li> <li>NHS Hull CCG</li> <li>NHS North Kirklees CCG</li> <li>Welsh Government</li> </ul>	<p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>Evidence Review Group tbc</li> <li>National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>Public Health England</li> <li>Public Health Wales NHS Trust</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are:

manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.